The notices it replaced
- Reissues: PAR-23-314 Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
- 2 steps back: PAR-20-314 Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
- 3 steps back: PAR-18-310 Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 - Clinical Trials Not Allowed
- 4 steps back: PAR-15-096 Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH3)
Replaced by PAR-28-042.
Who won it before
8 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,719,262 in first-year total cost, median $342,111.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RPRB-8 (J2)]2
- Special Emphasis Panel[ZCA1 RPRB-Z (J2)]1
- Special Emphasis Panel[ZCA1 RPRB-Z (O1)]1
- Special Emphasis Panel[ZCA1 TCRB-9 (J1)]1
- Special Emphasis Panel[ZCA1 TCRB-J (J2)]1
Most frequent institutions
- BAYLOR COLLEGE OF MEDICINE1
- CEDARS-SINAI MEDICAL CENTER1
- FRED HUTCHINSON CANCER RESEARCH CENTER1
- JOHNS HOPKINS UNIVERSITY1
- NORTHERN MICHIGAN UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Validation, translation, and clinical implementation of a gene expression biomarker to predict meningioma outcomes and radiotherapy responses1UH3CA298962-01 · under PAR-23-314 | RALEIGH, DAVID R | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $315,066 | ZCA1 |
| 2025 | Validation of the Diagnostic and Predictive Tool, D2HGlo, for the Quantification of the Oncometabolite D-2-Hydroxyglutarate (D-2-HG) in Glioma1UH3CA297234-01 · under PAR-23-314 | JENNINGS, MATTHEW JAMESKAMSON, DAVID OLAYINKAPEKAR, JAMES J.PRATT, EVAN PATRICK SAUVIE | NORTHERN MICHIGAN UNIVERSITY, MI | $194,787 | ZCA1 |
| 2023 | Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial1UH3CA276603-01A1 · under PAR-20-314 | SYMMANS, WILLIAM F | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $369,718 | ZCA1 |
| 2023 | Validation of Clinical Assays for Risk Stratification of Children With Pediatric Liver Neoplasms1UH3CA271227-01A1 · under PAR-20-314 | LOPEZ-TERRADA, DOLORES | BAYLOR COLLEGE OF MEDICINE, TX | $333,001 | ZCA1 |
| 2022 | APPLICATION OF A MULTIPLEXED IMMUNOASSAY FOR THE DETECTION OF BLADDER CANCER1UH3CA271377-01 · under PAR-20-314 | ROSSER, CHARLES J | CEDARS-SINAI MEDICAL CENTER, CA | $458,020 | ZCA1 |
| 2022 | Validation of the MHC II Immune Activation Assay in Breast Cancer1UH3CA262221-01A1 · under PAR-20-314 | BERNARD, PHILIP SVARLEY, KATHERINE ELENA | UNIVERSITY OF UTAH, UT | $351,220 | ZCA1 |
| 2019 | Evaluation of commercially available prostate cancer assays to accelerate novel applications in active surveillance1UH3CA234196-01 · under PAR-18-310 | LIN, DANIEL W.ZHENG, YINGYE | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $365,856 | ZCA1 |
| 2019 | Developing a CLIA compliant LDT for detecting plasma piR-Ls/pfeRNAs to distinguish benign and malignant lung nodules1UH3CA239137-01 · under PAR-18-310 | BROCK, MALCOLM VMEI, YUPING | JOHNS HOPKINS UNIVERSITY, MD | $331,594 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.